Bruker faced a tough 2024, with aggressive M&A, $600M preferred issuance, rising debt, and execution issues prompting a ...
Great. Can everyone hear me? Can everyone hear us? Okay. Fantastic. Welcome, everyone. It's great to have you. Welcome, Gerald Herman, CFO of Bruker. I'm Aisyah Noor, European medtech analyst with ...
Forbes contributors publish independent expert analyses and insights. Dr. Tracy Brower writes about joy, community and the future of work. Gen Alpha is growing up fast and it’s time to focus on who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback